Plus Therapeutics Expands CNSide Assay Platform to State of California

2 weeks ago

CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

2 weeks ago

CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas…

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

2 weeks ago

PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic…

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

2 weeks ago

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts…

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

2 weeks ago

JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

2 weeks ago

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose…

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

2 weeks ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for…

Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

2 weeks ago

Financing led by 5AM Ventures, OrbiMed, and Monograph Capital to drive development of a broad portfolio of proprietary obesity programs…

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

2 weeks ago

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile…